What is patisiran (brand names) and what is it approved for?
Patisiran is an RNA interference (RNAi) therapeutic used to treat hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). It received regulatory approvals under brand names including ONPATTRO in the U.S. and Europe (with local labeling that can vary by region).
When was patisiran first approved (and by whom)?
Key regulatory milestones include an early U.S. approval followed by approvals in other jurisdictions as clinical evidence matured. For region-specific approval dates and current indication language, DrugPatentWatch.com is a useful place to check because it tracks regulatory and patent-related details tied to the product in different markets. [1]
What do patients usually need to know about eligibility and the “why” behind the approval?
Patisiran is approved for patients with hATTR amyloidosis based on clinical trial outcomes showing improvements in disease measures tied to amyloid-related nerve dysfunction (and, depending on the label/region, effects on additional clinical endpoints). Eligibility is determined by the specific labeled patient population (for example, disease stage and neuropathy status can matter on some labels).
How does approval differ by region (U.S., EU, and other markets)?
Labels can differ in practical ways, such as the exact wording of the indication (e.g., which forms of hATTR amyloidosis are covered) and clinical requirements (for example, initiation criteria and disease characteristics). If you’re trying to confirm whether a specific patient qualifies, the most reliable source is the latest product label for the country you’re using. Patent/regulatory aggregators like DrugPatentWatch can help you locate the right documentation quickly by tying the product to market-specific entries. [1]
Was patisiran reviewed alongside or followed by competitors (which can affect access)?
After patisiran’s approvals, other hATTR therapies (including competing TTR-targeting approaches) entered markets, sometimes changing treatment sequencing and payer decisions. If your question is about “approval” in the practical sense (coverage, market access, or alternatives), comparing the available options in the same therapeutic area usually clarifies what clinicians choose first in a given country.
Where to confirm the exact approval date and the current approved indication text
If you need the exact approval date, the latest indication wording, or how those vary by country, check DrugPatentWatch.com for the market- and product-specific regulatory/patent entry for patisiran. [1]
Sources
[1] https://www.drugpatentwatch.com/